Skip to main content
Affluent Medical logo

Affluent Medical — Investor Relations & Filings

Ticker · AFME ISIN · FR0013333077 LEI · 969500N30CO4B5N2GN67 PA Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2024-08-22 Regulatory Filings
Country FR France
Listing PA AFME

About Affluent Medical

https://www.affluentmedical.com

Affluent Medical is a clinical-stage medical technology company that develops innovative, minimally invasive implants designed to restore essential physiological functions. The company's activities are concentrated in two primary therapeutic areas: structural heart disease and urology. It specifically addresses severe mitral valve insufficiency and urinary incontinence. The product pipeline, currently in clinical development, features three key devices: Kalios™, an adjustable annuloplasty ring for mitral valve repair; Epygon™, a biomimetic mitral valve for replacement procedures; and Artus™, an electronic artificial urinary sphincter for treating urinary incontinence. Affluent Medical's technologies are engineered to be adjustable and biomimetic, allowing for implantation via minimally invasive surgery and adaptation to both the patient's anatomy and the progression of their pathology.

Recent filings

Filing Released Lang Actions
Affluent Medical to attend German Fall Conference in Frankfurt in September 2024
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Affluent Medical SA will attend the 'German Fall Conference' in September 2024. It details the company's presentation schedule and topics to be covered (achievements, growth plans, milestones). This type of announcement, informing the market about participation in an investor conference where updates will be shared, is best classified as an Investor Presentation (IP) announcement or related material, as it is focused on communicating with investors and analysts about future plans and recent progress, rather than being a formal regulatory filing like a 10-K or an ER. However, since the document itself is an announcement *about* attending a conference where presentations will occur, and it is not the presentation itself, it fits best under the general category for investor communications or regulatory announcements. Given the options, it is an announcement regarding investor engagement and future outlook presentation. It is not a formal financial report (10-K, IR, ER, MRQ). It is not a management discussion (MDA) or a formal proxy (DEF 14A). Since it is a specific announcement about an upcoming investor event where the company will present updates, it aligns closely with the spirit of Investor Presentation (IP) materials, but as a news release about attending, it could also be RNS. Given the content focuses heavily on what will be presented to investors (achievements, outlook), IP is a strong candidate, but RNS is the safest general regulatory announcement category for non-standard filings. Since the content is about presenting updates at a conference, and it is not a formal financial report, I will classify it as an Investor Presentation (IP) announcement, as it directly relates to investor outreach and presentation of company strategy/updates.
2024-08-22 English
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to a declaration of crossing shareholding thresholds, dated July 18, 2024. It explicitly states that Edwards Lifesciences Holding Inc. crossed the 5% threshold of capital and voting rights in AFFLUENT MEDICAL. This type of filing, reporting changes in significant share ownership by an entity, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal regulatory disclosure regarding ownership changes, not a general regulatory announcement (RNS) or a report itself.
2024-07-19 French
Affluent Medical announces the availability of a prospectus for the admission to trading of 6,190,831 shares issued as part of a capital increase without preferential subscription rights in favour of
Share Issue/Capital Change Classification · 98% confidence The document is a press release announcing the availability of a prospectus following a capital increase without preferential subscription rights. Key phrases include 'announces the availability of a prospectus', 'Capital Increase', and details about the issuance of new shares and resulting shareholder distribution changes. This announcement relates directly to the company's financing activities and capital structure change, specifically the issuance of new shares following a capital increase. This aligns best with the 'Capital/Financing Update' (CAP) category, as it details the execution and immediate impact of a financing event. While it mentions a prospectus (which could suggest RPA or LTR if it were just an announcement of a report), the core subject is the capital raise itself, making CAP more specific. It is not a general regulatory filing (RNS) because the subject matter is highly specific to financing.
2024-07-15 English
Affluent Medical signs agreements for mitral valve technologies with EUR 15M upfront payment.
M&A Activity Classification · 99% confidence The document is a press release dated July 12, 2024, announcing significant business agreements between Affluent Medical and Edwards Lifesciences, involving an upfront payment of EUR 15 million, an exclusive option agreement, a non-exclusive license, and a capital increase where Edwards will acquire an equity stake. This announcement details a major financing/investment activity and a strategic partnership. This fits best under the 'Capital/Financing Update' category (CAP), as it explicitly details a capital increase and investment from a strategic partner. While it involves licensing IP, the primary focus of the announcement is the financial transaction and equity stake acquisition.
2024-07-12 English
Affluent Medical conclut des accords sur ses technologies de valve mitrale moyennant un paiement initial de 15 millions d'euros.
M&A Activity Classification · 99% confidence The document is a press release dated July 12, 2024, announcing that Affluent Medical has concluded several agreements with Edwards Lifesciences concerning its mitral valve technologies. The announcement details an upfront payment of 15 million euros, an exclusive option to purchase a subsidiary, a non-exclusive license for IP, and a capital increase where Edwards will become a shareholder (9.21%). This type of announcement, detailing significant corporate transactions, financing activities, and strategic partnerships, fits best under the 'Capital/Financing Update' category, as it explicitly involves a capital increase and strategic investment, even though it also covers licensing and options. Since it is a direct announcement of a financial/corporate event rather than a periodic report (like 10-K or IR) or a general regulatory filing (RNS), CAP is the most appropriate code. The length (6997 chars) confirms it is the primary content, not just a brief announcement of a report.
2024-07-12 French
Affluent Medical signs agreements for mitral valve technologies with EUR 15M upfront payment
Share Issue/Capital Change Classification · 99% confidence The document is a news release dated July 12, 2024, announcing significant business agreements between Affluent Medical SA and Edwards Lifesciences, involving an upfront payment of EUR 15 million, an exclusive option agreement, a global license agreement, and a capital increase where Edwards will take an equity stake. This type of announcement details corporate transactions, financing activities (the capital increase), and strategic partnerships. It is not a formal regulatory report like a 10-K or IR, nor is it a transcript or a simple dividend notice. The closest fit among the provided definitions is 'Capital/Financing Update' (CAP) due to the explicit mention of a capital increase and equity stake acquisition, which is a core financing activity. It could also be considered a general Regulatory Filing (RNS) as it is disseminated via EQS News, but CAP is more specific to the content involving fundraising/capital structure changes.
2024-07-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.